The effect of ezetimibe and low dose atorvastatin on myocardial injury after PCI in patients with unstable angina pectoris and the mechanism

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-13003830

Enrollment

Unknown

Registered

2013-11-19

Start date

2013-11-20

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

unstable angina pectoris

Interventions

1:atorvastatin20mg/day

2:ezetimibe10mg/day+atorvastatin20mg/day

3:atorvastatin40mg/day

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: The patient who has symptom of typical angina pectoris and/or ST-T dynamic change in ECG; the male or unpregnant female between 18 and 80 years old.

Exclusion criteria

Exclusion criteria: 1. acute myocardial infarction(less than 3 months); 2. one of the myocardial injure marker rise (include CK-MB, troponin Imyohemoglobin); 3. cardiac insufficiency,EF265umol/L; 5. once prior used statin and ezetimibe; 6. active liver diserse or abnormal hepatic function(ALT or AST rise); 7. unexplained myodyniamyastheniaor CK rise 1.5-times normal levels; 8. join other clinical reseach 9. don't implant stent.

Design outcomes

Primary

Measure	Time frame
myocardial injure marker;	—

Secondary

Measure	Time frame
high-sensitive c-reactive protein;	—

Countries

China

Contacts

Public ContactLiuquan

The first hospital of Jilin University

quanliu888@163.com+86 13756661271

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026